Free Trial

Design Therapeutics (DSGN) Competitors

Design Therapeutics logo
$3.77 +0.09 (+2.45%)
As of 07/3/2025 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DSGN vs. LENZ, OCS, COGT, SNDX, CMRX, CDMO, ORIC, QURE, AVXL, and IMNM

Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include LENZ Therapeutics (LENZ), Oculis (OCS), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Chimerix (CMRX), Avid Bioservices (CDMO), Oric Pharmaceuticals (ORIC), uniQure (QURE), Anavex Life Sciences (AVXL), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.

Design Therapeutics vs. Its Competitors

Design Therapeutics (NASDAQ:DSGN) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

LENZ Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/A-$49.59M-$0.99-3.81
LENZ TherapeuticsN/AN/A-$49.77M-$1.77-18.38

Design Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 6.10%. LENZ Therapeutics has a consensus price target of $46.60, indicating a potential upside of 43.23%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Design Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
LENZ Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by company insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Design Therapeutics. LENZ Therapeutics' average media sentiment score of 0.93 beat Design Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Design Therapeutics Neutral
LENZ Therapeutics Positive

Design Therapeutics' return on equity of -22.85% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Design TherapeuticsN/A -22.85% -22.02%
LENZ Therapeutics N/A -23.74%-22.65%

Design Therapeutics has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Summary

Design Therapeutics beats LENZ Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DSGN vs. The Competition

MetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$214.02M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E Ratio-3.8121.5627.6520.23
Price / SalesN/A283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book0.887.538.035.65
Net Income-$49.59M-$55.14M$3.18B$249.15M
7 Day Performance5.60%4.61%2.93%3.28%
1 Month Performance-5.99%0.90%1.72%3.95%
1 Year Performance10.23%5.40%34.39%20.98%

Design Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DSGN
Design Therapeutics
0.3635 of 5 stars
$3.77
+2.4%
$4.00
+6.1%
+10.2%$214.02MN/A-3.8140
LENZ
LENZ Therapeutics
1.3424 of 5 stars
$30.48
+1.8%
$46.60
+52.9%
+80.2%$842.70MN/A-17.22110
OCS
Oculis
1.7287 of 5 stars
$19.65
+1.9%
$35.33
+79.8%
+62.6%$841.81M$780K-7.442News Coverage
COGT
Cogent Biosciences
2.5922 of 5 stars
$7.26
+0.4%
$14.57
+100.7%
-9.8%$823.18MN/A-3.9580News Coverage
Analyst Revision
SNDX
Syndax Pharmaceuticals
3.1224 of 5 stars
$9.19
-3.1%
$35.91
+290.7%
-55.7%$815.73M$23.68M-2.38110
CMRX
Chimerix
0.6197 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6863 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
ORIC
Oric Pharmaceuticals
4.2376 of 5 stars
$10.00
+7.4%
$19.17
+91.7%
+40.1%$793.44MN/A-5.3580
QURE
uniQure
2.1206 of 5 stars
$13.95
-1.8%
$37.82
+171.1%
+277.2%$778.36M$27.12M-3.18500News Coverage
AVXL
Anavex Life Sciences
3.6022 of 5 stars
$9.30
+2.3%
$44.00
+373.1%
+155.8%$776.03MN/A-16.9140Positive News
IMNM
Immunome
2.4317 of 5 stars
$8.74
-0.1%
$23.33
+167.0%
-27.6%$761.36M$10.94M-2.7540

Related Companies and Tools


This page (NASDAQ:DSGN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners